Commercial opportunities for emerging infectious diseases vaccine developers

Although development of interventions for emerging infectious diseases (EIDs) has traditionally been limited by a lack of market incentives, novel funding mechanisms and global partnerships for outbreak preparedness are expanding the commercial prospects for vaccine developers, according to analytics company GlobalData

picture of

Breaking News

Russian syringe maker is looking for manufacturing site in Belarus

Ural Medical Company and other manufacturers are looking to make connections between the countries

Encube Ethicals opens new topical manufacturing facility

The 205 sqm facility in Goa caters for topical products, including those containing HPAPIs

Vetter’s Skokie facility expansion nears completion

The expansion features storage space increase of 3,100 sqft, including a freezer farm as well as a planned walk-in ...

Pharmapack Europe review: Sizeable growth potential in 2019

Patient-centricity, eco-friendly and smart packaging trends mark the biggest growth drivers and innovations in 2019

Enesi and Oxford Vaccine Group partner to immunise against plague

Collaboration aims to create an easy-to-use solid dose plague vaccine for use in areas of outbreak and as a defence ...

Sirio Pharma eyes global R&D collaboration

China's CDMO plans to combine the expertise of its 100+ scientist based in Asia, Europe and the US

Supporting precision with precision

As biologics steadily grow in pipeline development and commercialisation, they inherently require precise and ...

GiroNEX designs precision powder dispenser

The technology could be used in localised manufacturing to allow more tailored treatment

Mylan and Hospira voluntarily recall injectables

Glass and copper salts were found in the companies’ injectable medications but no adverse reactions have been ...

Bacteria as ingredients in skincare products: a manufacturing challenge

The concept of friendly bacteria is now well embedded in the public’s imagination, and various food and drinks ...

A new paradigm in vaccines and cancer treatments

Specialist pharmaceutical company N4 Pharma is developing Nuvec, a unique non-viral adjuvant delivery system for ...

Platform solutions for biotech pharmaceuticals

Today’s innovative pharmaceuticals and new approaches to cell or gene therapies offer new treatment solutions for ...

Catalent invests US$27 million to commercialise Zydis Ultra

Zydis Ultra is Catalent's next-generation oral disintegrating tablet (ODT) technology

Akili and Shionogi sign deal to expand digital medicine to Asia

Treatment for ADHD and autism dosed by an action video game is under review by the US FDA and has already found a ...